| Application: | Internal Medicine |
|---|---|
| Usage Mode: | For oral administration |
| Suitable for: | Elderly, Children, Adult |
| State: | Solid |
| Shape: | Capsules |
| Type: | Organic Chemicals |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier Mycophenolate Mofetil Capsule
Indication
Mycophenolate mofetil is suitable for preventing organ rejection in patients receiving allogeneic kidney or liver transplantation. Mycophenolate mofetil should be applied simultaneously with cyclosporine A or tacrolimus and corticosteroids.
Usage and Dosage
Kidney Transplantation Adult: For kidney transplant patients, oral dose of 1g bid (2g daily dose) is recommended. Although 1.5 g per dose (daily dose 3 g) was used in clinical trials and it was safe and effective, there was no effective advantage in kidney transplantation. Patients who received 2 g of mycophenolate mofetil per day had better overall safety than those who received 3 g.
Liver Transplantation: The recommended oral dose for adult liver transplant patients is 0.5-1g bid (1-2g daily dose). Transplantation of mycophenolate mofetil should begin as soon as possible after kidney, heart or liver transplantation. Food had no effect on MPAAUC but decreased MPACmax by 40%. Therefore, it is recommended that mycophenolate be taken on an empty stomach. However, for stable renal transplant patients, mycophenolate mofetil can be taken with food if needed.
Patients with abnormal liver kinetics: Renal transplantation patients with severe hepatic parenchymal disease do not need dose adjustment. However, it is unclear if other liver diseases need to be dose-adjusted. There are no data on heart transplant patients with severe hepatic parenchymal lesions. Elderly: The recommended recommended dose for kidney transplantation is 1 g bid, and for liver transplant patients 0.5-1 g bid. Dose Adjustment For kidney transplant patients with severe chronic renal impairment (glomerular filtration rate less than 25 ml/min/1.73 m2), after the early postoperative period, doses greater than 1 g per bid should be avoided. And these patients need close observation. Patients with delayed graft function after renal transplantation do not need to adjust doses (see Pharmacology and Toxicology, Pharmacokinetics, and Precautions). Patients with severe chronic renal insufficiency who have undergone heart or liver transplantation are not available. If the potential benefit is greater than the potential harm, mycophenolate mofetil can be used after a heart or liver transplant in patients with severe chronic renal insufficiency. If there is neutropenia (absolute neutrophil count 1.3×10 3 /μL), mycophenolate mofetil should be suspended or reduced, and appropriate diagnostic tests and appropriate treatment.
Contraindications
Allergic reactions to this drug have been observed, so mycophenolate mofetil is contraindicated in patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid, or other components of the drug. Mycophenolate mofetil intravenous formulations are contraindicated in patients with hypersensitivity to polysorbate 80 (Tween).
Our factory
This product is produced in our GMP factory, all our facility has past China GMP, and also officially certificated by more than ten countries' MOH.
Our Service
We can specially develop the products per customers' specification.
We can offer OEM service with customers' private brands and labels.
We can offer excellent after-sale service and professional technical support.
Our Quality control system
In manufacturing, quality is what sustains our life. Starting from the material selection, there are many factors that contribute to the quality control process. Our manufacturing facility is GMP certified. Quality Control (QC) and monitoring procedures are built into every aspect of our work.
Our Quality Control System is outlined below:
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}